Bio-Rad Laboratories, Inc.

NYSE:BIO Rapport sur les actions

Capitalisation boursière : US$7.5b

Bio-Rad Laboratories Croissance future

Future contrôle des critères 1/6

Bio-Rad Laboratories devrait augmenter ses bénéfices et son chiffre d'affaires de 3.6% et de 1.7% par an respectivement. Le BPA devrait croître de de 3.6% par an. Le rendement des capitaux propres devrait être 2.9% dans 3 ans.

Informations clés

3.6%

Taux de croissance des bénéfices

3.64%

Taux de croissance du BPA

Life Sciences croissance des bénéfices17.5%
Taux de croissance des recettes1.7%
Rendement futur des capitaux propres2.93%
Couverture par les analystes

Low

Dernière mise à jour19 May 2026

Mises à jour récentes de la croissance future

Article d’analyse • Aug 03

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Investors in Bio-Rad Laboratories, Inc. ( NYSE:BIO ) had a good week, as its shares rose 7.7% to close at US$285...

Recent updates

Mise à jour du récit • May 15

BIO: Share Repurchases Will Support Future Upside Despite Lower Margin Outlook

Analysts have trimmed their price target on Bio-Rad Laboratories from $321.25 to $293.00, reflecting updated views on growth, margins, discount rate, and future P/E assumptions. What's in the News From January 1, 2026 to March 31, 2026, Bio-Rad Laboratories repurchased 176,257 shares for US$47.42 million, equal to 0.65% of its shares.
Mise à jour du récit • Apr 29

BIO: Completed Buybacks And Intangible Impairment Will Support Future Upside

Analysts maintained their $320.00 price target for Bio-Rad Laboratories, making only minor adjustments to assumptions for discount rate, revenue, profit margin, and future P/E ratio to support this unchanged outlook. What's in the News Reported impairment charges of purchased intangibles and related items of $172.8 million for the fourth quarter ended December 31, 2025 (Key Developments).
Mise à jour du récit • Apr 15

BIO: Buybacks And Intangible Impairment Will Shape Balanced Forward Expectations

Analysts have reset their price target on Bio-Rad Laboratories from $375 to $320, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43 million under the buyback program announced on July 20, 2023 (Key Developments).
Mise à jour du récit • Mar 31

BIO: Share Repurchase And Higher Margin Outlook Will Support Future Upside

Analysts have reduced their price target on Bio-Rad Laboratories from $348.00 to $321.25, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that result in a slightly more conservative valuation framework. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback that was announced on July 20, 2023 (Key Developments).
Mise à jour du récit • Mar 17

BIO: Share Repurchases And Intangible Impairment Will Shape Future Upside

Analysts have maintained their $375.00 price target for Bio-Rad Laboratories, citing only minor adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated model inputs rather than a change in their overall view. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).
Mise à jour du récit • Mar 03

BIO: Share Repurchases And Margin Outlook Will Support Future Upside

Analysts have maintained their price target for Bio-Rad Laboratories at $375, citing updated assumptions that include slightly higher revenue, improved profit margins, and a lower future P/E multiple, which together support the unchanged assessment of fair value. What's in the News From October 1, 2025 to December 31, 2025, Bio-Rad Laboratories reported no additional share repurchases, with 0 shares bought for $0, under its existing buyback program (Key Developments).
Mise à jour du récit • Feb 17

BIO: Share Repurchases Will Support Future Upside Despite Impairment Charges

Analysts are keeping their price target for Bio-Rad Laboratories steady at $375, with updated assumptions that include a slightly higher discount rate, a higher revenue growth outlook, a lower profit margin, and a higher future P/E multiple to reflect their latest view of the risk and return profile. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of the company, for a total of US$715.43 million under the buyback announced on July 20, 2023 (Key Developments).
Mise à jour du récit • Feb 03

BIO: Fair Outlook Will Balance Richer Margins Against Higher Required Returns

Analysts have lifted their price target on Bio-Rad Laboratories from US$265 to US$325, reflecting updated views on slightly different growth assumptions, a higher projected profit margin, and an adjusted future P/E multiple. Valuation Changes Fair Value: updated from US$265 to US$325, indicating a higher implied valuation level.
Seeking Alpha • Jan 22

Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth

Summary Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the latter's bioprocessing business is looking better of late. Management's guidance has been volatile, with 2025 core revenue growth targets fluctuating from 2.5% to near zero, then modestly rebounding. ddPCR is a bright spot, but broader revenue growth remains constrained; I see fair value at $338–$390, with rerating contingent on sustained growth. Read the full article on Seeking Alpha
Mise à jour du récit • Jan 20

BIO: Share Buybacks And Oncology Assay Partnership Will Drive Future Upside

Analysts have kept their price target for Bio-Rad Laboratories broadly steady at about US$375.00, reflecting only slight adjustments to modeled discount rate, revenue growth, profit margin, and future P/E assumptions in their updated views. What's in the News From July 1, 2025 to September 30, 2025, Bio-Rad repurchased 212,578 shares, about 0.79% of its shares, for US$52.83 million under its existing buyback program.
Article d’analyse • Jan 06

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Key Insights Bio-Rad Laboratories' estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Current...
Mise à jour du récit • Jan 06

BIO: Share Buybacks And Oncology Partnership Will Support Future Upside

Analysts have lowered their price target on Bio-Rad Laboratories from US$437 to US$375, based on updated assumptions that combine more moderate revenue growth expectations with a slightly higher discount rate and a lower future P/E, partially offset by a higher projected profit margin. What's in the News Completed share repurchase of 2,614,132 shares, or 9.26% of the company, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).
Mise à jour du récit • Dec 14

BIO: Share Repurchase Will Drive Attractive Shareholder Returns Ahead

Narrative Update on Bio-Rad Laboratories Analysts have reaffirmed their conviction in Bio-Rad Laboratories, with the price target effectively unchanged at approximately 348 dollars. Modest tweaks to the discount rate, long-term revenue growth, profit margin, and future valuation assumptions largely offset one another in updated models.
Mise à jour du récit • Nov 28

BIO: Share Repurchase and Expanded Partnership Will Shape Performance in Coming Quarters

Analysts have maintained their price target for Bio-Rad Laboratories at $348.00, noting only minor adjustments to revenue growth and profit margin expectations this quarter. What's in the News Bio-Rad Laboratories completed the repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for $715.43 million under a buyback program announced in July 2023.
Mise à jour du récit • Nov 14

BIO: Share Repurchase and Expanded Partnerships Will Influence Future Performance

Analysts have raised their price target for Bio-Rad Laboratories from $324 to $348. They cite updated financial assumptions as well as small shifts in projected growth rates and profitability.
Mise à jour du récit • Oct 30

BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook

Analysts have raised their price target for Bio-Rad Laboratories from $310 to $324, reflecting updated profit margin estimates. These changes more than offset slightly lower revenue growth expectations.
Mise à jour du récit • Sep 28

Molecular Diagnostics Expansion Will Unlock Potential While Cost Challenges Persist

The decline in Bio-Rad Laboratories’ consensus price target to $310.00 primarily reflects lower future P/E and revenue growth expectations. What's in the News Completed buyback of 2,401,554 shares (8.47% of outstanding) for $662.6 million under program announced July 2023.
Article d’analyse • Aug 03

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Investors in Bio-Rad Laboratories, Inc. ( NYSE:BIO ) had a good week, as its shares rose 7.7% to close at US$285...
Article d’analyse • Jul 14

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
User avatar
Nouveau récit • May 13

Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics

Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.
Seeking Alpha • Jan 29

Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential

Summary Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin leverage over the long term, and there are only a handful of meaningful revenue drivers with above-average potential. I believe BIO management has long been too conservative and unfocused with its R&D spending, but recent commentary suggests that growth potential and ROI will play a bigger role going forward. Bio-Rad's stake in Sartorius remains a significant store of value, but management's long-term plans remain unclear. While undervalued and having potential for longer-term growth upside, I remain cautious due to management and strategic concerns, as well as a large reliance on Sartorius to drive overall value. Read the full article on Seeking Alpha
Seeking Alpha • Nov 25

Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis

Summary Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net sales are expected to decline in 2024. Valuing Bio-Rad using a discounted cash flow model indicates that the BIO stock is overvalued by 20.10%. Read the full article on Seeking Alpha
Seeking Alpha • Sep 23

Bio-Rad Laboratories: Overvalued Given Current Growth Prospects

Summary Bio-Rad Laboratories is buying back a considerable amount of its own stock given the shares' current valuation and growth prospects. Profits and sales are expected to rebound in FY2025. A fuller look at Bio-Rad Laboratories is provided in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jul 14

Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar

Summary Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research and clinical diagnostics products. The company's stock has been underperforming due to various pressures, including its position in Sartorius AG. Despite potential catalysts like product launches, the stock is considered overvalued with weak returns on capital and declining margins. Read the full article on Seeking Alpha
Seeking Alpha • Apr 14

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Summary Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the life sciences space have been challenging, driving, double-digit declines in Bio-Rad's Life Sciences segment, and neither biopharma nor academic/government budgets look great for 2024. Bio-Rad's holdings in Sartorius bring significant value to the company, but Sartorius shares have sold off considerably since the bioproduction bubble popped and investor enthusiasm has faded. There's an interesting some-of-the-parts story here, particularly if bioproduction growth resumes after a period of capacity digestion, but it's hard to love Bio-Rad on a standalone basis. Read the full article on Seeking Alpha
Seeking Alpha • Oct 25

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Summary Bio-Rad Laboratories' investment returns are expected to be hindered by economic and technical factors. The company's large ownership in Sartorius AG has been a hindrance due to the latter's poor performance and high correlations between the pair. Bio-Rad's business returns are not attractive nor economically valuable, leading the market to push its equity value further to the downside. Read the full article on Seeking Alpha

Prévisions de croissance des bénéfices et des revenus

NYSE:BIO - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20282,6762283264673
12/31/20272,6362303154465
12/31/20262,5692253164615
3/31/20262,590169357510N/A
12/31/20252,583760375532N/A
9/30/20252,558-676337492N/A
6/30/20252,554319348534N/A
3/31/20252,541-2,164332515N/A
12/31/20242,567-1,844266455N/A
9/30/20242,580-779224412N/A
6/30/20242,563-1,326177346N/A
3/31/20242,605-322185347N/A
12/31/20232,671-637218375N/A
9/30/20232,720-159223374N/A
6/30/20232,769-428153287N/A
3/31/20232,779-191125242N/A
12/31/20222,802-3,62780194N/A
9/30/20222,805-6,021152286N/A
6/30/20222,871-1,930364505N/A
3/31/20222,896-91459606N/A
12/31/20212,9234,254536670N/A
9/30/20212,9806,659670783N/A
6/30/20212,8804,045590689N/A
3/31/20212,7014,098533626N/A
12/31/20202,5463,814480585N/A
9/30/20202,3803,521378450N/A
6/30/20202,2941,947323414N/A
3/31/20202,3291,579383478N/A
12/31/20192,3121,759N/A458N/A
9/30/20192,304377N/A403N/A
6/30/20192,289905N/A366N/A
3/31/20192,292574N/A288N/A
12/31/20182,289366N/A285N/A
9/30/20182,2941,277N/A250N/A
6/30/20182,2831,030N/A216N/A
3/31/20182,212767N/A201N/A
12/31/20172,160122N/A104N/A
9/30/20172,11017N/A130N/A
6/30/20172,08513N/A153N/A
3/31/20172,09726N/A168N/A
12/31/20162,06826N/A216N/A
9/30/20162,06798N/A157N/A
6/30/20162,02897N/A188N/A
3/31/20162,018108N/A149N/A
12/31/20152,019109N/A186N/A
9/30/20152,047103N/A190N/A
6/30/20152,10897N/A199N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de BIO ( 3.6% par an) est supérieure au taux d'épargne ( 3.5% ).

Bénéfices vs marché: Les bénéfices de BIO ( 3.6% par an) devraient croître plus lentement que le marché US ( 16.8% par an).

Croissance élevée des bénéfices: Les bénéfices de BIO devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de BIO ( 1.7% par an) devrait croître plus lentement que le marché de US ( 11.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de BIO ( 1.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de BIO devrait être faible dans 3 ans ( 2.9 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/20 16:39
Cours de l'action en fin de journée2026/05/20 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Bio-Rad Laboratories, Inc. est couverte par 19 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Jon WoodBofA Global Research
Yuan ZhiB. Riley Securities, Inc.
Patrick DonnellyCitigroup Inc